{
  "report_rows": [
    {
      "kpi": "Q2 Adjusted (non-GAAP) Operating EPS",
      "prediction": "IN-LINE",
      "answer": "pred ~$0.44 vs. cons ~$0.44",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Q2 Total Revenue",
      "prediction": "MISS",
      "answer": "pred ~$5.65B vs. cons ~$5.72B",
      "confidence": "LOW"
    },
    {
      "kpi": "FFO-to-Debt / Credit Metric (annualized run-rate)",
      "prediction": "MISS",
      "answer": "pred ~13.5% vs. cons/target ~14.0%",
      "confidence": "MEDIUM"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY2026 Adjusted EPS Guidance Range",
      "prediction": "UNCHANGED",
      "answer": "guide ~$2.81-$2.91 (midpoint $2.86) vs. cons $2.85 (FY2026)",
      "confidence": "HIGH"
    },
    {
      "kpi": "Long-term EPS Growth Algorithm (Rate Base CAGR)",
      "prediction": "UNCHANGED",
      "answer": "guide ~7.9% (top end of 5-7% EPS algo) vs. cons ~6.0% (2026-2029)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "4-Year Transmission/Total Capital Plan",
      "prediction": "BETTER",
      "answer": "guide ~$41.7B vs. cons/prior plan ~$40.0B (2026-2029)",
      "confidence": "MEDIUM"
    }
  ],
  "day1_residual_pct": -0.8,
  "day1_confidence": "LOW",
  "day5_residual_pct": -1.8,
  "day5_path": "FADE",
  "day5_rationale": "EPS is almost fully pre-guided (CFO flagged ~15% of $2.86 midpoint = ~$0.43-0.44), so the headline print is unlikely to surprise; the stock's reaction will instead hinge on regulatory/credit commentary. Estimates have already drifted down 6-8% over 30/90 days, and out-year models still need to absorb the PECO rate-case delay, a possible unfavorable Pepco MD order, and any further Moody's/S&P action on PECO/BGE. Even a muted or slightly positive day-1 reaction is likely to fade over the week as sell-side analysts trim 2027-2028 EPS/rate-base assumptions for the credit and PA/MD regulatory friction, similar to the post-Q1 pattern where a beat still produced a ~2.5% decline.",
  "day5_confidence": "MEDIUM"
}